Different Roles of TM5, TM6, and ECL3 in the Oligomerization and Function of Human ABCG2

Overview

Journal Biochemistry

Specialty Biochemistry

Date 2012 Apr 14

PMID 22497316

Citations 8

Authors

Wei Mo

Jing Qi

Jian-Ting Zhang

Affiliations

Soon will be listed here.

Abstract

ABCG2 is a member of the ATP-binding cassette transporter superfamily, and its overexpression causes multidrug resistance (MDR) in cancer chemotherapy. ABCG2 may also protect cancer stem cells by extruding cytotoxic materials. ABCG2 has previously been shown to exist as a high-order homo-oligomer consisting of possibly 8-12 subunits, and the oligomerization domain was mapped to the C-terminal domain, including TM5, ECL3, and TM6. In this study, we further investigate this domain in detail for the role of each segment in the oligomerization and drug transport function of ABCG2 using domain swapping and site-directed mutagenesis. We found that none of the three segments (TM5, TM6, and ECL3) is essential for the oligomerization activity of ABCG2 and that any one of these three segments in the full-length context is sufficient to support ABCG2 oligomerization. While TM5 plays an important role in the drug transport function of ABCG2, TM6 and ECL3 are replaceable. Thus, each segment in the TM5-ECL3-TM6 domain plays a distinctive role in the oligomerization and function of ABCG2.

Citing Articles

Structure of a dimeric full-length ABC transporter.

Bickers S, Benlekbir S, Rubinstein J, Kanelis V Nat Commun. 2024; 15(1):9946.

PMID: 39550367 PMC: 11569179. DOI: 10.1038/s41467-024-54147-8.

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells.

Gao H, Cui Q, Wang J, Ashby Jr C, Chen Y, Shen Z Front Pharmacol. 2023; 14:1235285.

PMID: 37521473 PMC: 10373739. DOI: 10.3389/fphar.2023.1235285.

Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs.

Zhang W, Yang Y, Dong Z, Shi Z, Zhang J J Biol Chem. 2019; 294(52):20222-20232.

PMID: 31719146 PMC: 6937587. DOI: 10.1074/jbc.RA119.008347.

Human bile acid transporter ASBT (SLC10A2) forms functional non-covalent homodimers and higher order oligomers.

Chothe P, Czuba L, Moore R, Swaan P Biochim Biophys Acta Biomembr. 2017; 1860(3):645-653.

PMID: 29198943 PMC: 5780253. DOI: 10.1016/j.bbamem.2017.11.016.

The multidrug transporter ABCG2: still more questions than answers.

Horsey A, Cox M, Sarwat S, Kerr I Biochem Soc Trans. 2016; 44(3):824-30.

PMID: 27284047 PMC: 4900755. DOI: 10.1042/BST20160014.

References

Yang Y, Li Z, Mo W, Ambadipudi R, Arnold R, Hrncirova P . Human ABCC1 interacts and colocalizes with ATP synthase α, revealed by interactive proteomics analysis. J Proteome Res. 2011; 11(2):1364-72. PMC: 8283941. DOI: 10.1021/pr201003g. View

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

KYTE J, Doolittle R . A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982; 157(1):105-32. DOI: 10.1016/0022-2836(82)90515-0. View

Sal-Man N, Gerber D, Shai Y . The identification of a minimal dimerization motif QXXS that enables homo- and hetero-association of transmembrane helices in vivo. J Biol Chem. 2005; 280(29):27449-57. DOI: 10.1074/jbc.M503095200. View

Kage K, Fujita T, Sugimoto Y . Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci. 2005; 96(12):866-72. PMC: 11159771. DOI: 10.1111/j.1349-7006.2005.00126.x. View

Yang Y, Chen Q, Zhang J . Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1. J Biol Chem. 2002; 277(46):44268-77. DOI: 10.1074/jbc.M207003200. View

Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T . Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer. 2002; 97(5):626-30. DOI: 10.1002/ijc.10100. View

Yang Y, Liu Y, Dong Z, Xu J, Peng H, Liu Z . Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1. J Biol Chem. 2007; 282(12):8821-30. DOI: 10.1074/jbc.M700152200. View

Xu J, Peng H, Chen Q, Liu Y, Dong Z, Zhang J . Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res. 2007; 67(9):4373-81. DOI: 10.1158/0008-5472.CAN-06-3169. View

10.

Zhang J . Biochemistry and pharmacology of the human multidrug resistance gene product, ABCG2. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007; 32(4):531-41. View

11.

Sal-Man N, Gerber D, Shai Y . The composition rather than position of polar residues (QxxS) drives aspartate receptor transmembrane domain dimerization in vivo. Biochemistry. 2004; 43(8):2309-13. DOI: 10.1021/bi0356294. View

12.

Gottesman M, Ambudkar S, Ni B, Aran J, Sugimoto Y, Cardarelli C . Exploiting multidrug resistance to treat cancer. Cold Spring Harb Symp Quant Biol. 1994; 59:677-83. DOI: 10.1101/sqb.1994.059.01.078. View

13.

Liu Y, Yang Y, Qi J, Peng H, Zhang J . Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. J Pharmacol Exp Ther. 2008; 326(1):33-40. PMC: 2632310. DOI: 10.1124/jpet.108.138115. View

14.

Mo W, Zhang J . Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol. 2012; 3(1):1-27. PMC: 3325772. View

15.

Doyle L, Yang W, Abruzzo L, Krogmann T, Gao Y, Rishi A . A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998; 95(26):15665-70. PMC: 28101. DOI: 10.1073/pnas.95.26.15665. View

16.

Yang Y, Mo W, Zhang J . Role of transmembrane segment 5 and extracellular loop 3 in the homodimerization of human ABCC1. Biochemistry. 2010; 49(51):10854-61. PMC: 3095655. DOI: 10.1021/bi101350x. View

17.

Zhang J, Chen M, Han E, Wang C . Dissection of de novo membrane insertion activities of internal transmembrane segments of ATP-binding-cassette transporters: toward understanding topological rules for membrane assembly of polytopic membrane proteins. Mol Biol Cell. 1998; 9(4):853-63. PMC: 25312. DOI: 10.1091/mbc.9.4.853. View

18.

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

19.

Xu J, Peng H, Zhang J . Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy. Curr Med Chem. 2007; 14(6):689-701. DOI: 10.2174/092986707780059580. View

20.

Giri N, Agarwal S, Shaik N, Pan G, Chen Y, Elmquist W . Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos. 2008; 37(3):560-70. PMC: 2680510. DOI: 10.1124/dmd.108.022046. View